The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a more substantial loss in body mass and enhance metabolic function, p